First, there would be private payers that could afford the drug. Second, I recall that ARIAD stated that no suitable patient will be denied iclusig, so some support or discount is likely.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.